These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Strosberg J; Kunz PL; Hendifar A; Yao J; Bushnell D; Kulke MH; Baum RP; Caplin M; Ruszniewski P; Delpassand E; Hobday T; Verslype C; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Paganelli G; Severi S; Morse M; Metz DC; Ansquer C; Courbon F; Al-Nahhas A; Baudin E; Giammarile F; Taïeb D; Mittra E; Wolin E; O'Dorisio TM; Lebtahi R; Deroose CM; Grana CM; Bodei L; Öberg K; Polack BD; He B; Mariani MF; Gericke G; Santoro P; Erion JL; Ravasi L; Krenning E; Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2372-2382. PubMed ID: 32123969 [TBL] [Abstract][Full Text] [Related]
9. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy, Survival, and Safety of [ Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192 [No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983 [TBL] [Abstract][Full Text] [Related]
12. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Strosberg J; Wolin E; Chasen B; Kulke M; Bushnell D; Caplin M; Baum RP; Kunz P; Hobday T; Hendifar A; Oberg K; Sierra ML; Thevenet T; Margalet I; Ruszniewski P; Krenning E; J Clin Oncol; 2018 Sep; 36(25):2578-2584. PubMed ID: 29878866 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of peptide receptor radionuclide therapy with Kobayashi N; Takano S; Ito K; Sugiura M; Ogawa M; Takeda Y; Okubo N; Suzuki A; Tokuhisa M; Kaneta T; Utsunomiya D; Hata M; Inoue T; Hosono M; Kinuya S; Ichikawa Y Ann Nucl Med; 2021 Dec; 35(12):1332-1341. PubMed ID: 34533700 [TBL] [Abstract][Full Text] [Related]
14. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results. Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):8-9. PubMed ID: 27168104 [No Abstract] [Full Text] [Related]
16. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569 [TBL] [Abstract][Full Text] [Related]